Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood

Brain and Development

Volumn 35, Issue 8, 2013, Pages 778-785

  Takahashi, Yukitoshi ^a,b   Yamazaki, Etsuko ^a   Mine, Jun ^a   Kubota, Yuko ^a   Imai, Katsumi ^a   Mogami, Yuki ^a   Baba, Koichi ^a   Matsuda, Kazumi ^a   Oguni, Hirokazu ^c   Sugai, Kenji ^d   Ohtsuka, Yoko ^e   Fujiwara, Tateki ^a   Inoue, Yushi ^a  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^e OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cognitive outcome; Functional hemispherectomy; IVIG therapy; Motor outcome; Rasmussen syndrome; Seizure outcome; Steroid pulse therapy; Tacrolimus

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; TACROLIMUS;

ARTICLE; CHILDHOOD DISEASE; COGNITION; EARLY DIAGNOSIS; FEMALE; HEMISPHERECTOMY; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; RASMUSSEN SYNDROME; SEIZURE; STEROID THERAPY;

COGNITIVE OUTCOME; FUNCTIONAL HEMISPHERECTOMY; IVIG THERAPY; MOTOR OUTCOME; RASMUSSEN SYNDROME; SEIZURE OUTCOME; STEROID-PULSE THERAPY; TACROLIMUS;

CHILD; CHILD, PRESCHOOL; COGNITION; ENCEPHALITIS; FEMALE; HEMISPHERECTOMY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; MALE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84881370160     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2013.01.010     Document Type: Article

References (12)

1. Rasmussen T., Olszewski J., Lloyd-Smith D. Focal seizures due to chronic localized encephalitis. Neurology 1958, 8:435-445.
2. Bien C.G., Granata T., Antozzi C., Cross J.H., Dulac O., Kurthen M., et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005, 128:454-471.
3. Takahashi Y. Infections as causative factors of epilepsy. Future Neurol 2006, 1:291-302.
4. Bien C.G., Bauer J., Deckwerth T.L., Wiendl H., Deckert M., Wiestler O.D., et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's syndrome. Ann Neurol 2002, 51:311-318.
5. Takahashi Y., Mine J., Kubota Y., Yamazaki E., Fujiwara T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNFα, and granzyme B in CSF. Epilepsia 2009, 50:1419-1431.
6. Oguni H., Andermann F., Rasmussen T.B. The syndrome of chronic encephalitis and epilepsy. A study based on the MNI series of 48 cases. Adv Neurol 1992, 57:419-433.
7. Bien C.G., Widman G., Urbach H., Sassen R., Kuczaty S., Wiestler O.D., et al. The natural history of Rasmussen's encephalitis. Brain 2002, 125:1751-1759.
8. Yamazaki E., Takahashi Y., Akasaka N., Fujiwara T., Inoue Y. Temporal changes in brain MRI findings in Rasmussen syndrome. Epileptic Disord 2011, 13:229-239.
9. Villani F., Spreafico R., Farina L., Giovagnoli A.R., Bernasconi P., Granata T., et al. Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis. Neurology 2001, 56:248-250.
10. Granata T., Fusco L., Gobbi G., Freri E., Ragona F., Broggi G., et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 2003, 61:1807-1810.
11. Hart Y.M., Cortez M., Andermann F., Hwang P., Fish D.R., Dulac O., et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994, 44:1030-1036.
12. Bien C.G., Gleissner U., Sassen R., Widman G., Urbach H., Elger C.E. An open study of tacrolimus therapy in Rasmussen's encephalitis. Neurology 2004, 62:2106-2109.